324 related articles for article (PubMed ID: 26640324)
1. Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.
Desterke C; Martinaud C; Ruzehaji N; Le Bousse-Kerdilès MC
Mediators Inflamm; 2015; 2015():415024. PubMed ID: 26640324
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.
Martinaud C; Desterke C; Konopacki J; Vannucchi AM; Pieri L; Guglielmelli P; Dupriez B; Ianotto JC; Boutin L; Lataillade JJ; Le Bousse-Kerdilès MC
Genom Data; 2015 Sep; 5():1-2. PubMed ID: 26484208
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC;
Pathol Biol (Paris); 2001 Mar; 49(2):153-7. PubMed ID: 11317961
[TBL] [Abstract][Full Text] [Related]
5. Primary myelofibrosis and the "bad seeds in bad soil" concept.
Le Bousse-Kerdilès MC
Fibrogenesis Tissue Repair; 2012; 5(Suppl 1):S20. PubMed ID: 23259918
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA; Salama ME; Carreau N; Tremblay D; Verstovsek S; Mesa R; Hoffman R; Mascarenhas J
Haematologica; 2016 Jun; 101(6):660-71. PubMed ID: 27252511
[TBL] [Abstract][Full Text] [Related]
7. Focus on Osteosclerotic Progression in Primary Myelofibrosis.
Spampinato M; Giallongo C; Romano A; Longhitano L; La Spina E; Avola R; Scandura G; Dulcamare I; Bramanti V; Di Rosa M; Vicario N; Parenti R; Li Volti G; Tibullo D; Palumbo GA
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33477816
[TBL] [Abstract][Full Text] [Related]
8. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC
Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
[TBL] [Abstract][Full Text] [Related]
9. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.
Lataillade JJ; Pierre-Louis O; Hasselbalch HC; Uzan G; Jasmin C; Martyré MC; Le Bousse-Kerdilès MC;
Blood; 2008 Oct; 112(8):3026-35. PubMed ID: 18669872
[TBL] [Abstract][Full Text] [Related]
10. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.
Desterke C; Martinaud C; Guerton B; Pieri L; Bogani C; Clay D; Torossian F; Lataillade JJ; Hasselbach HC; Gisslinger H; Demory JL; Dupriez B; Boucheix C; Rubinstein E; Amsellem S; Vannucchi AM; Le Bousse-Kerdilès MC
Haematologica; 2015 Jun; 100(6):757-67. PubMed ID: 25840601
[TBL] [Abstract][Full Text] [Related]
11. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of myelofibrosis with myeloid metaplasia.
Tefferi A
J Clin Oncol; 2005 Nov; 23(33):8520-30. PubMed ID: 16293880
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models.
Chagraoui H; Wendling F; Vainchenker W
Best Pract Res Clin Haematol; 2006; 19(3):399-412. PubMed ID: 16781480
[TBL] [Abstract][Full Text] [Related]
14. Homing efficiency and hematopoietic reconstitution of bone marrow-derived stroma cells expanded by recombinant human macrophage-colony stimulating factor in vitro.
Jin-Xiang F; Xiaofeng S; Jun-Chuan Q; Yan G; Xue-Guang Z
Exp Hematol; 2004 Dec; 32(12):1204-11. PubMed ID: 15588945
[TBL] [Abstract][Full Text] [Related]
15. Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion.
Tripodo C; Sangaletti S; Guarnotta C; Piccaluga PP; Cacciatore M; Giuliano M; Franco G; Chiodoni C; Sciandra M; Miotti S; Calvaruso G; Carè A; Florena AM; Scotlandi K; Orazi A; Pileri SA; Colombo MP
Blood; 2012 Oct; 120(17):3541-54. PubMed ID: 22955913
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and management of idiopathic myelofibrosis.
Reilly JT
Baillieres Clin Haematol; 1998 Dec; 11(4):751-67. PubMed ID: 10640215
[TBL] [Abstract][Full Text] [Related]
17. Properties of myelofibrosis-derived fibroblasts.
Castro-Malaspina H; Jhanwar SC
Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
[TBL] [Abstract][Full Text] [Related]
18. IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.
Longhitano L; Tibullo D; Vicario N; Giallongo C; La Spina E; Romano A; Lombardo S; Moretti M; Masia F; Coda ARD; Venuto S; Fontana P; Parenti R; Li Volti G; Di Rosa M; Palumbo GA; Liso A
Aging (Albany NY); 2021 Dec; 13(23):25055-25071. PubMed ID: 34905501
[TBL] [Abstract][Full Text] [Related]
19. Stem cell dysregulation in myelofibrosis with myeloid metaplasia: current data on growth factor and transcription factor involvement.
Martyré MC; Le Bousse-Kerdilès MC;
Semin Oncol; 2005 Aug; 32(4):373-9. PubMed ID: 16202683
[TBL] [Abstract][Full Text] [Related]
20. PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis.
Augello C; Gianelli U; Falcone R; Tabano S; Savi F; Bonaparte E; Ciboddo M; Paganini L; Parafioriti A; Ricca D; Lonati S; Cattaneo D; Fracchiolla NS; Iurlo A; Cortelezzi A; Bosari S; Miozzo M; Sirchia SM
Leuk Res; 2015 Feb; 39(2):236-41. PubMed ID: 25498506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
